DSP30

DSP30 is a phosphorothioate cpG-oligodeoxynucleotide and a TLR9 agonist. DSP30 can activate immune system cells, including B cells and dendritic cells, by inducing proliferation and cytokine production.DSP30 can enhance the immunosuppressive function of bone marrow-multipotent mesenchymal stromal cells (BM-MSC) . DSP30 combined with interleukin 2 (IL2) is an effective mitotic stimulant in B-cell disorders. DSP30 can be used for the genetic characteristic research and analysis of chronic lymphocytic leukemia (CLL) [1][2][3][4][5].

Product Specifications

UNSPSC

12352208

Target

Mitosis; Toll-like Receptor (TLR)

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

[TCGTCGCTGTCTCCGCTTCTTCTTGCCH]

References & Citations

[1]Sangiorgi B, et al. DSP30 enhances the immunosuppressive properties of mesenchymal stromal cells and protects their suppressive potential from lipopolysaccharide effects: A potential role of adenosine. Cytotherapy. 2016 Jul;18 (7) :846-59.|[2]Dun KA, et al. DSP30 and interleukin-2 as a mitotic stimulant in B-cell disorders including those with a low disease burden. Genes Chromosomes Cancer. 2018 May;57 (5) :260-267.|[3]Haferlach C, et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV (H) status and immunophenotyping. Leukemia. 2007 Dec;21 (12) :2442-51.|[4]Annunziato F, et al. Reversal of human allergen-specific CRTH2+ T (H) 2 cells by IL-12 or the PS-DSP30 oligodeoxynucleotide. J Allergy Clin Immunol. 2001 Nov;108 (5) :815-21.|[5]Decker T, et al. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood. 2002 Feb 15;99 (4) :1320-6.